Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320356 | 0.88 | GPR119 (0.49) | GPR119GRM5LRRK2PDK1PDK2 | |
| SCHEMBL10120506 | 0.84 | GPR119 (0.55) | GPR119LRRK2 | |
| SCHEMBL10120542 | 0.82 | GPR119 (0.42) | GPR119GRM5SLC22A12LRRK2PDK1 | |
| SCHEMBL15381343 | 0.82 | GPR119 (0.54) | GPR119 | |
| SCHEMBL10120666 | 0.81 | GPR119 (0.59) | GPR119LRRK2 | |
| SCHEMBL15381348 | 0.78 | GPR119 (0.52) | GPR119LRRK2 | |
| SCHEMBL10134274 | 0.78 | GPR119 (0.53) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL10121102 | 0.76 | GPR119 (0.50) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL10120548 | 0.76 | GPR119 (0.72) | GPR119 | |
| SCHEMBL4268138 | 0.76 | DYRK1A (0.43) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| WO-2010114958-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885GRM5 261/4885SLC22A12 1953/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | GPR119 1/4885GRM5 286/4885SLC22A12 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.